Spero Therapeutics, Inc.

SPRO ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Balance Sheet
Annual Quarterly

Balance Sheet

Line Item Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024
Assets
Cash & Equivalents $50.8M $56.1M $40.3M $48.6M $31.2M $48.9M $52.9M $76.3M
Accounts Receivable — — — — — — — —
Inventory — — — — — — — —
Total Current Assets $51.6M $57.6M $67.3M $52.3M $59.4M $74.7M $107.3M $131.6M
Property, Plant & Equipment — — — — — — $0 $0
Goodwill — — — — — — — —
Intangible Assets (Excl. Goodwill) — — — — — — — —
Total Assets $52.8M $59.0M $68.9M $54.2M $62.1M $77.7M $110.5M $135.2M
Liabilities
Accounts Payable $155.0K $217.0K $693.0K $1.4M $780.0K $1.8M $7.3M $6.1M
Total Current Liabilities $8.4M $5.5M $8.9M $13.6M $14.9M $29.2M $49.1M $49.1M
Long-Term Debt — — — — — — — —
Total Liabilities $8.6M $6.1M $9.9M $27.7M $29.3M $43.9M $64.4M $69.7M
Stockholders' Equity
Retained Earnings $-467.8M $-458.3M $-451.1M $-482.6M $-475.2M $-473.5M $-459.6M $-438.8M
Total Stockholders' Equity $44.2M $52.9M $59.0M $26.5M $32.8M $33.8M $46.1M $65.5M
← Newer Page 1 of 5 Older →